> Details

Spasov, Neofit J.; Dombrowski, Frank; Lode, Holger N.; Spasova, Mariya; Ivanova, Liliya; Mumdjiev, Ivan; Burnusuzov, Hassan; Siebert, Nikolai

First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
  • Contributor: Spasov, Neofit J.; Dombrowski, Frank; Lode, Holger N.; Spasova, Mariya; Ivanova, Liliya; Mumdjiev, Ivan; Burnusuzov, Hassan; Siebert, Nikolai
  • Published: Ovid Technologies (Wolters Kluwer Health), 2022
  • Published in: Journal of Pediatric Hematology/Oncology, 44 (2022) 6, Seite e948-e953
  • Language: English
  • DOI: 10.1097/mph.0000000000002488
  • ISSN: 1077-4114
  • Origination:
  • Footnote:
  • Description: Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation.